These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23794545)

  • 1. Corifollitropin α followed by menotropin for poor ovarian responders' trial (COMPORT): a protocol of a multicentre randomised trial.
    Polyzos NP; Camus M; Llacer J; Pantos K; Tournaye H
    BMJ Open; 2013 Jun; 3(6):. PubMed ID: 23794545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
    Polyzos NP; Devos M; Humaidan P; Stoop D; Ortega-Hrepich C; Devroey P; Tournaye H
    Fertil Steril; 2013 Feb; 99(2):422-6. PubMed ID: 23084565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders.
    Polyzos NP; Corona R; Van De Vijver A; Blockeel C; Drakopoulos P; Vloeberghs V; De Vos M; Camus M; Humaidan P; Tournaye H
    Gynecol Endocrinol; 2015; 31(11):885-90. PubMed ID: 26172925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study comparing corifollitropin alfa associated with hp-HMG versus high dose rFSH antagonist protocols for ovarian stimulation in poor responders.
    Mendret-Pellerin S; Leperlier F; Reignier A; Lefebvre T; Barrière P; Fréour T
    Hum Fertil (Camb); 2020 Jun; 23(2):93-100. PubMed ID: 30129813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?
    Errázuriz J; Drakopoulos P; Pening D; Racca A; Romito A; De Munck N; Tournaye H; De Vos M; Blockeel C
    Reprod Biomed Online; 2019 Jun; 38(6):1010-1017. PubMed ID: 30879911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial.
    Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F
    Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders.
    Moffat R; Hansali C; Schoetzau A; Ahler A; Gobrecht U; Beutler S; Raggi A; Sartorius G; De Geyter C
    Hum Reprod; 2021 Mar; 36(4):987-997. PubMed ID: 33367742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
    Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC;
    Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol.
    Salgueiro LL; Rolim JR; Moura BR; Machado SP; Haddad C
    JBRA Assist Reprod; 2016 Aug; 20(3):123-6. PubMed ID: 27584604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction.
    Park HY; Lee MY; Jeong HY; Rho YS; Song SJ; Choi BC
    Clin Exp Reprod Med; 2015 Jun; 42(2):62-6. PubMed ID: 26161335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial.
    Taronger R; Martínez-Cuenca S; Ferreros I; Rubio JM; Fernández-Colom PJ; Martínez-Triguero ML; Pellicer A
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():192-197. PubMed ID: 30428403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.